We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > OlympiA

News List

IDMC Concluded Lynparza Trial Crossed Superiority Boundary for Invasive Disease-Free Survival americanpharmaceuticalreview
February 20, 2021
The OlympiA Phase III trial for AstraZeneca and MSD’s Lynparza will move to early primary analysis and reporting following a recommendation from the Independent Data Monitoring Committee (IDMC).
Lynparza crosses superiority boundary for invasive disease-free survival at interim analysis europeanpharmaceuticalreview
February 19, 2021
The OlympiA trial will conduct its primary analysis early, after the Independent Data Monitoring Committee found it met its primary endpoint in BRCA mutated early breast cancer patients.